NO2118279T3 - - Google Patents

Info

Publication number
NO2118279T3
NO2118279T3 NO08727718A NO08727718A NO2118279T3 NO 2118279 T3 NO2118279 T3 NO 2118279T3 NO 08727718 A NO08727718 A NO 08727718A NO 08727718 A NO08727718 A NO 08727718A NO 2118279 T3 NO2118279 T3 NO 2118279T3
Authority
NO
Norway
Application number
NO08727718A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2118279T3 publication Critical patent/NO2118279T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO08727718A 2007-01-16 2008-01-16 NO2118279T3 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88521207P 2007-01-16 2007-01-16
PCT/US2008/051123 WO2008089212A1 (en) 2007-01-16 2008-01-16 Novel composition for treating metabolic syndrome

Publications (1)

Publication Number Publication Date
NO2118279T3 true NO2118279T3 (zh) 2018-04-21

Family

ID=39636359

Family Applications (1)

Application Number Title Priority Date Filing Date
NO08727718A NO2118279T3 (zh) 2007-01-16 2008-01-16

Country Status (22)

Country Link
US (1) US8431552B2 (zh)
EP (2) EP2118279B1 (zh)
JP (1) JP5271918B2 (zh)
KR (1) KR101460820B1 (zh)
CN (1) CN101631859B (zh)
AR (1) AR065837A1 (zh)
AU (1) AU2008206328B2 (zh)
BR (1) BRPI0806774A2 (zh)
CA (1) CA2675638C (zh)
DK (1) DK2118279T3 (zh)
ES (1) ES2660173T3 (zh)
IL (1) IL199903A (zh)
MX (1) MX2009007720A (zh)
MY (1) MY154869A (zh)
NO (1) NO2118279T3 (zh)
NZ (1) NZ578891A (zh)
RU (1) RU2486902C2 (zh)
SG (1) SG178716A1 (zh)
TR (1) TR201802359T4 (zh)
TW (2) TWI629058B (zh)
WO (1) WO2008089212A1 (zh)
ZA (1) ZA200904972B (zh)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070092577A1 (en) * 2005-10-03 2007-04-26 University Of Tennessee Research Foundation Dietary calcium for reducing the production of reactive oxygen species
WO2008091710A2 (en) * 2007-01-26 2008-07-31 Washington University Methods and compositions for treating neuropathies
EP2291182A1 (en) * 2008-05-13 2011-03-09 Genmedica Therapeutics SL Salicylate conjugates useful for treating metabolic disorders
CA2666036C (en) * 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases
AU2009313657A1 (en) * 2008-11-04 2010-05-14 Metaproteomics, Llc Phytochemical compositions and methods for activating AMP-kinase
KR100922519B1 (ko) * 2008-11-12 2009-10-20 대원제약주식회사 펠루비프로펜을 함유하는 용출률 및 안정성이 개선된 경구투여용 약제학적 제제
CA2755072A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination therapies for treating metabolic disorders
CN102395359A (zh) * 2009-03-16 2012-03-28 Ipintl有限责任公司 治疗阿尔茨海默病和骨质疏松症以及减缓衰老
BRPI1013878A2 (pt) 2009-03-16 2016-04-05 Genmedica Therapeutics Sl método para tratar distúrbios metabólicos, e, composto
US8486922B2 (en) * 2010-04-28 2013-07-16 Chien-Hung Chen Composition
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
EP2705842A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating parkinson's disease
KR20140054066A (ko) 2011-07-15 2014-05-08 뉴서트 사이언시스, 인크. 대사 경로 조절을 위한 조성물 및 방법
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
KR102200176B1 (ko) * 2012-05-08 2021-01-11 에어로믹스, 인코포레이티드 신규 방법
US20140024708A1 (en) * 2012-07-17 2014-01-23 Banavara L. Mylari Ursolic acid salts for treating diabetes and obesity
US9636329B2 (en) * 2012-11-06 2017-05-02 Northwestern University Methods of treating cancer with glut inhibitors and oxidative phosphorylation inhibitors
CA2891335C (en) 2012-11-13 2021-05-04 Nusirt Sciences, Inc. Compositions and methods for increasing energy metabolism
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
EP2968466B1 (en) * 2013-03-13 2018-07-25 F.Hoffmann-La Roche Ag Formulations with reduced oxidation
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
RU2015143438A (ru) * 2013-03-15 2017-04-21 АЛС МАУНТИН ЭлЭлСи Фармацевтическая композиция, содержащая активатор амрк и серотонинергическое средство, и способы ее применения
BR112015023310A2 (pt) 2013-03-15 2017-07-18 Nusirt Sciences Inc composições, métodos e kits para redução de níveis lipídicos
EP3065729A4 (en) 2013-11-06 2017-05-31 Aeromics, Inc. Novel formulations
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
US10155003B2 (en) 2014-05-05 2018-12-18 The Board Of Regents Of The University Of Texas System Methods and compositions comprising ursolic acid and/or resveratrol for treating diabetes, or cancer
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
WO2016054365A1 (en) * 2014-10-01 2016-04-07 Als Mountaiin Llc Pharmaceutical composition comprising aspirin, metformin, and serotonin with non-ionic surfactant
CN107530302A (zh) * 2015-03-04 2018-01-02 丹娜法伯癌症研究院 Melk的水杨酸酯抑制剂和使用方法
US11337932B2 (en) 2016-12-20 2022-05-24 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
US20180193283A1 (en) 2016-12-20 2018-07-12 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
JP2021529737A (ja) 2018-06-20 2021-11-04 エルテーエス ローマン テラピー−ジステーメ アーゲー アセナピンを含有する経皮治療システム
WO2020115765A1 (en) 2018-12-05 2020-06-11 Celagenex Research (India) Pvt. Ltd. Novel synergistic composition comprising sirt1 and ampk activators for treating metabolic syndrome
CN115350184A (zh) * 2020-01-10 2022-11-18 康圣博施医药有限公司 药物的治疗组合以及其使用方法
US20220133700A1 (en) * 2020-10-29 2022-05-05 Thomas Winston Compositions and methods for treating neurological disorders
CN115703772A (zh) * 2021-08-09 2023-02-17 天地恒一制药股份有限公司 艾拉莫德共晶，及其制备方法与应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3914250A (en) 1974-08-01 1975-10-21 American Home Prod 1,4-Diazepino{8 6,5,4-jk{9 carbazoles
US5100919A (en) 1984-03-19 1992-03-31 The Rockefeller University Biguanides and derivatives thereof as inhibitors of advanced glycosylation of a target protein
US5385915A (en) 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
GB9311132D0 (en) 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
DE4409411A1 (de) * 1994-03-18 1995-09-28 Oped Gmbh Orthopaedische Produ Verpackungsbehälter
EP0692252B1 (en) 1994-06-14 2001-04-04 "Raffinerie Tirlemontoise", société anonyme: Use of a composition containing inulin or oligofructose in cancer treatment
DE9414065U1 (de) 1994-08-31 1994-11-03 Roehm Gmbh Thermoplastischer Kunststoff für darmsaftlösliche Arznei-Umhüllungen
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5981168A (en) 1998-05-15 1999-11-09 The University Of British Columbia Method and composition for modulating amyloidosis
US20040053900A1 (en) 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
BR0009026A (pt) 1999-03-19 2003-03-05 Knoll Gmbh Método de tratamento de distúrbio alimentìcio
US6589944B1 (en) 1999-04-05 2003-07-08 City Of Hope Breakers of advanced glycation endproducts
US6495538B2 (en) 1999-06-23 2002-12-17 Zinc Therapeutics, Canada Inc. Zinc ionophores as therapeutic agents
DE19949319A1 (de) 1999-10-13 2001-06-13 Ruetgers Vft Ag Verfahren zur Herstellung von Arylalkylethern
EP1097716A1 (en) * 1999-11-03 2001-05-09 Chronolife Inc. Dietary anti-adiposity food supplements and drugs based on thyrotropin-releasing hormone (TRH)
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
GB0004003D0 (en) 2000-02-22 2000-04-12 Knoll Ag Therapeutic agents
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US6927223B1 (en) 2000-05-26 2005-08-09 Washington State University Research Foundation Use of serotonin agents for adjunct therapy in the treatment of cancer
JP4180365B2 (ja) 2000-07-31 2008-11-12 エフ．ホフマン−ラ ロシュ アーゲー ピペラジン誘導体
YU8803A (sh) * 2000-08-07 2006-01-16 Ranbaxy Signature L.L.C. Tečni oblik metformina
AU2002221670B2 (en) 2000-10-16 2006-11-02 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-HT2 receptor ligands
AU2002227170A1 (en) 2000-11-03 2002-05-15 Wyeth Cycloalkyl(b)(1,4)diazepino(6,7,1-hi)indoles and derivatives
WO2002038142A2 (en) * 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Serotonergic compositions and methods for treatment of mild cognitive impairment
AU2426602A (en) 2000-11-20 2002-05-27 Biovitrum Ab Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
JP4204315B2 (ja) 2000-11-20 2009-01-07 ビオヴィトルム・アクチボラゲット（プブリクト） セロトニン５−ｈｔ２レセプターのアンタゴニストとしてのピペラジニルピラジン化合物
GB0030710D0 (en) 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
KR100539143B1 (ko) 2000-12-27 2005-12-26 에프. 호프만-라 로슈 아게 인돌 유도체 및 그의 5-ｈｔ2ｂ 및 5-ｈｔ2ｃ 수용체리간드로서의 용도
US20020137787A1 (en) * 2001-03-21 2002-09-26 Geho W. Blair Prevention or treatment of complications related to non-insulin dependent diabetes mellitus or type 2 diabetes mellitus
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
EP1302465A1 (en) 2001-10-11 2003-04-16 BRACCO IMAGING S.p.A. Enhanced substrate imaging by reversible binding to a paramagnetic complex
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US20060147947A1 (en) 2002-12-04 2006-07-06 Javier Apfeld AMPK pathway components
US20040204472A1 (en) * 2003-03-04 2004-10-14 Pharmacia Corporation Treatment and prevention of obesity with COX-2 inhibitors alone or in combination with weight-loss agents
US7329638B2 (en) 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
WO2005009412A1 (en) 2003-07-24 2005-02-03 Wockhardt Limited Oral compositions for treatment of diseases
US20050054731A1 (en) 2003-09-08 2005-03-10 Franco Folli Multi-system therapy for diabetes, the metabolic syndrome and obesity
US20080194019A1 (en) 2003-09-09 2008-08-14 Beth Israel Deaconess Medical Center, Inc. Tumor Suppressor Lkb1 Kinase Directly Activates Amp-Activated Kinase
US7244843B2 (en) * 2003-10-07 2007-07-17 Bristol-Myers Squibb Company Modulators of serotonin receptors
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
AU2005259864A1 (en) 2004-06-30 2006-01-12 Combinatorx, Incorporated Methods and reagents for the treatment of metabolic disorders
WO2006021008A2 (en) 2004-08-20 2006-02-23 Lind Stuart E Ionophores as cancer chemotherapeutic agents
WO2006024492A2 (en) 2004-08-30 2006-03-09 Interstitial Therapeutics Medical implant provided with inhibitors of atp synthesis
US20070105790A1 (en) 2004-09-02 2007-05-10 Bionaut Pharmaceuticals, Inc. Pancreatic cancer treatment using Na+/K+ ATPase inhibitors
WO2006078698A1 (en) * 2005-01-19 2006-07-27 Cengent Therapeutics, Inc. 2-imidazolone and 2-imidazolidinone heterocyclic inhibitors of tyrosine phosphatases
AU2006206274A1 (en) * 2005-01-20 2006-07-27 Sirtris Pharmaceuticals, Inc. Use of sirtuin-activating compounds for treating flushing and drug induced weight gain
US20070149466A1 (en) 2005-07-07 2007-06-28 Michael Milburn Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CA2614664A1 (en) * 2005-07-14 2007-01-25 Franco Folli Daily dosage regimen for treating diabetes, obesity,metabolic syndrome and polycystic ovary syndrome
EP2404604B1 (en) 2006-01-05 2019-02-06 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
CN101395164A (zh) 2006-01-10 2009-03-25 罗伊·J·于 N-(膦酰基烷基)-氨基酸、其衍生物和组合物以及使用方法
CA2637069A1 (en) 2006-01-12 2007-07-19 Novartis Ag Combination of mtor inhibitor and antipolate compound
US7659281B2 (en) 2006-04-25 2010-02-09 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors
CA2666036C (en) 2008-05-16 2017-09-12 Chien-Hung Chen Novel compositions and methods for treating hyperproliferative diseases

Also Published As

Publication number Publication date
EP2118279B1 (en) 2017-11-22
TR201802359T4 (tr) 2018-03-21
TWI440456B (zh) 2014-06-11
CA2675638C (en) 2015-11-24
DK2118279T3 (en) 2018-02-26
SG178716A1 (en) 2012-03-29
RU2486902C2 (ru) 2013-07-10
KR101460820B1 (ko) 2014-11-11
CA2675638A1 (en) 2008-07-24
CN101631859A (zh) 2010-01-20
EP2118279A1 (en) 2009-11-18
MY154869A (en) 2015-08-14
NZ578891A (en) 2012-03-30
EP2118279A4 (en) 2010-04-14
MX2009007720A (es) 2013-03-22
TW200836715A (en) 2008-09-16
TWI629058B (zh) 2018-07-11
AU2008206328A1 (en) 2008-07-24
JP2010516689A (ja) 2010-05-20
EP2494967A1 (en) 2012-09-05
ES2660173T3 (es) 2018-03-21
US8431552B2 (en) 2013-04-30
IL199903A (en) 2016-06-30
CN101631859B (zh) 2017-10-13
WO2008089212A1 (en) 2008-07-24
IL199903A0 (en) 2010-04-15
AR065837A1 (es) 2009-07-08
BRPI0806774A2 (pt) 2011-09-13
US20080176822A1 (en) 2008-07-24
KR20090111323A (ko) 2009-10-26
TW201433315A (zh) 2014-09-01
AU2008206328B2 (en) 2013-10-31
JP5271918B2 (ja) 2013-08-21
ZA200904972B (en) 2010-09-29
RU2009131065A (ru) 2011-02-27

Similar Documents

Publication Publication Date Title
BRPI0818233A2 (zh)
CN300730237S (zh) 袋夹
CN300728163S (zh) 净水器(振忠)
CN300726251S (zh) 壁纸(3)
CN300726256S (zh) 墙纸(9a)
CN300726264S (zh) 墙纸(24a)
CN300726283S (zh) 玻璃板(第六印象)
CN300726621S (zh) 餐具(sh-0910)
CN300726841S (zh) 包装瓶(营养素2号)
CN300726959S (zh) 包装盒(铍立安)
CN300726985S (zh) 鞋盒
CN300727154S (zh) 铅笔包装袋(282)
CN300727233S (zh) 指纹识别器
CN300727406S (zh) 汽车用前保险杠
CN300727411S (zh) 后门饰板
CN300727515S (zh) 插座(电脑电源一键控pc04-10)
CN300727577S (zh) 数码相框(dpf700)
CN300727592S (zh) 电子笔
CN300727708S (zh) 滚筒疏松器
CN300727735S (zh) 洗衣机波轮
CN300727852S (zh) 儿童画板
CN300727864S (zh) 活动铅笔(tm028)
CN300728014S (zh) 电梯用液晶显示器
CN300728096S (zh) 遥控飞机模型
CN300730413S (zh) 玩具(振动语音枪248)